These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38654089)

  • 21. Apolipoprotein C-III Inhibition - Killing Two Birds with One Stone?
    Kraaijenhof JM; Stroes ESG
    NEJM Evid; 2023 Dec; 2(12):EVIDe2300239. PubMed ID: 38320505
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes.
    Digenio A; Dunbar RL; Alexander VJ; Hompesch M; Morrow L; Lee RG; Graham MJ; Hughes SG; Yu R; Singleton W; Baker BF; Bhanot S; Crooke RM
    Diabetes Care; 2016 Aug; 39(8):1408-15. PubMed ID: 27271183
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Apolipoprotein C-III: going back to the future for a lipid drug target.
    Huff MW; Hegele RA
    Circ Res; 2013 May; 112(11):1405-8. PubMed ID: 23704213
    [No Abstract]   [Full Text] [Related]  

  • 24. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
    D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
    Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Apolipoprotein AV does not contribute to hypertriglyceridaemia or triglyceride lowering by dietary fish oil and rosiglitazone in obese Zucker rats.
    Dorfmeister B; Brandlhofer S; Schaap FG; Hermann M; Fürnsinn C; Hagerty BP; Stangl H; Patsch W; Strobl W
    Diabetologia; 2006 Jun; 49(6):1324-32. PubMed ID: 16570166
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Updates in Drug Treatment of Severe Hypertriglyceridemia.
    Gouni-Berthold I; Schwarz J; Berthold HK
    Curr Atheroscler Rep; 2023 Oct; 25(10):701-709. PubMed ID: 37642858
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.
    Esan O; Wierzbicki AS
    Drug Des Devel Ther; 2020; 14():2623-2636. PubMed ID: 32753844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of ApoCIII: the next PCSK9?
    Bernelot Moens SJ; van Capelleveen JC; Stroes ES
    Curr Opin Lipidol; 2014 Dec; 25(6):418-22. PubMed ID: 25255477
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of apolipoprotein A5 and apolipoprotein C3 levels to serum triglycerides in patients with type 2 diabetes.
    Alborn WE; Prince MJ; Konrad RJ
    Clin Chim Acta; 2007 Mar; 378(1-2):154-8. PubMed ID: 17188674
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Plasma apolipoprotein A5 and triglycerides in type 2 diabetes.
    Dallinga-Thie GM; van Tol A; Hattori H; van Vark-van der Zee LC; Jansen H; Sijbrands EJ;
    Diabetologia; 2006 Jul; 49(7):1505-11. PubMed ID: 16752169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Loss-of-function mutations in APOC3, triglycerides, and coronary disease.
    ; Crosby J; Peloso GM; Auer PL; Crosslin DR; Stitziel NO; Lange LA; Lu Y; Tang ZZ; Zhang H; Hindy G; Masca N; Stirrups K; Kanoni S; Do R; Jun G; Hu Y; Kang HM; Xue C; Goel A; Farrall M; Duga S; Merlini PA; Asselta R; Girelli D; Olivieri O; Martinelli N; Yin W; Reilly D; Speliotes E; Fox CS; Hveem K; Holmen OL; Nikpay M; Farlow DN; Assimes TL; Franceschini N; Robinson J; North KE; Martin LW; DePristo M; Gupta N; Escher SA; Jansson JH; Van Zuydam N; Palmer CN; Wareham N; Koch W; Meitinger T; Peters A; Lieb W; Erbel R; Konig IR; Kruppa J; Degenhardt F; Gottesman O; Bottinger EP; O'Donnell CJ; Psaty BM; Ballantyne CM; Abecasis G; Ordovas JM; Melander O; Watkins H; Orho-Melander M; Ardissino D; Loos RJ; McPherson R; Willer CJ; Erdmann J; Hall AS; Samani NJ; Deloukas P; Schunkert H; Wilson JG; Kooperberg C; Rich SS; Tracy RP; Lin DY; Altshuler D; Gabriel S; Nickerson DA; Jarvik GP; Cupples LA; Reiner AP; Boerwinkle E; Kathiresan S
    N Engl J Med; 2014 Jul; 371(1):22-31. PubMed ID: 24941081
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Longitudinal analysis of haplotypes and polymorphisms of the APOA5 and APOC3 genes associated with variation in serum triglyceride levels: the Bogalusa Heart Study.
    Hallman DM; Srinivasan SR; Chen W; Boerwinkle E; Berenson GS
    Metabolism; 2006 Dec; 55(12):1574-81. PubMed ID: 17142127
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Large triglyceride-rich lipoproteins in hypertriglyceridemia are associated with the severity of acute pancreatitis in experimental mice.
    Zhang Y; He W; He C; Wan J; Lin X; Zheng X; Li L; Li X; Yang X; Yu B; Xian X; Zhu Y; Wang Y; Liu G; Lu N
    Cell Death Dis; 2019 Sep; 10(10):728. PubMed ID: 31570698
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elevated levels of triglyceride and triglyceride-rich lipoprotein triglyceride induced by a high-carbohydrate diet is associated with polymorphisms of APOA5-1131T>C and APOC3-482C>T in Chinese healthy young adults.
    Lin J; Fang DZ; Du J; Shigdar S; Xiao LY; Zhou XD; Duan W
    Ann Nutr Metab; 2011; 58(2):150-7. PubMed ID: 21646779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Mutations of APOC3 gene, metabolism of triglycerides and reduction of ischemic cardiovascular events].
    Pirillo A; Catapano AL
    G Ital Cardiol (Rome); 2015 May; 16(5):289-94. PubMed ID: 25994465
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Loss-of-function mutations in APOC3 and risk of ischemic vascular disease.
    Jørgensen AB; Frikke-Schmidt R; Nordestgaard BG; Tybjærg-Hansen A
    N Engl J Med; 2014 Jul; 371(1):32-41. PubMed ID: 24941082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fructose-induced hypertriglyceridemia in rhesus macaques is attenuated with fish oil or ApoC3 RNA interference.
    Butler AA; Price CA; Graham JL; Stanhope KL; King S; Hung YH; Sethupathy P; Wong S; Hamilton J; Krauss RM; Bremer AA; Havel PJ
    J Lipid Res; 2019 Apr; 60(4):805-818. PubMed ID: 30723097
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia.
    Guan Y; Hou X; Tian P; Ren L; Tang Y; Song A; Zhao J; Gao L; Song G
    Front Endocrinol (Lausanne); 2021; 12():646185. PubMed ID: 33967959
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Hypertriglyceridemia on Beta Cell Mass and Function in ApoC3 Transgenic Mice.
    Liu YZ; Cheng X; Zhang T; Lee S; Yamauchi J; Xiao X; Gittes G; Qu S; Jiang CL; Dong HH
    J Biol Chem; 2016 Jul; 291(28):14695-705. PubMed ID: 27226540
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ApoC-III Glycoforms Are Differentially Cleared by Hepatic TRL (Triglyceride-Rich Lipoprotein) Receptors.
    Kegulian NC; Ramms B; Horton S; Trenchevska O; Nedelkov D; Graham MJ; Lee RG; Esko JD; Yassine HN; Gordts PLSM
    Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2145-2156. PubMed ID: 31390883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.